IYR vs XBI
iShares US Real Estate ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.38% for IYR.
- • IYR pays a higher dividend yield (2.19%).
Side-by-side metrics
| Metric | IYR | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.19% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $4.09B | $8.30B |
YTD return | 10.31% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.07 | 1.09 |
P/E ratio | 28.72 | — |
Last price | $102.56 | $133.66 |
Inception | — | — |
Issuer | iShares | State Street |
IYR top holdings
| WELL | Welltower Inc | 10.14% |
| PLD | Prologis Inc | 9.14% |
| EQIX | Equinix Inc | 4.80% |
| DLR | Digital Realty Trust Inc | 4.78% |
| SPG | Simon Property Group Inc | 4.63% |
| AMT | American Tower Corp | 4.31% |
| O | Realty Income Corp | 4.28% |
| PSA | Public Storage | 3.52% |
| VTR | Ventas Inc | 3.08% |
| CBRE | CBRE Group Inc Class A | 3.06% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About IYR
IYR (iShares US Real Estate ETF) is US real estate companies and REITs. Managed by iShares, the fund carries $4.1B in assets under management, an expense ratio of 0.38%, a dividend yield of 2.19%. Its largest holding is Welltower Inc (WELL), which represents 10.1% of the portfolio. Real Estate is the fund's largest sector exposure at 99.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.